Contrastingly, those treated with monotherapy saw tumor recurrence after therapeutic cessation.53 Success of these inhibitors in murine models has led to a clinical trial [NCT03605550] studying the therapeutic efficacy of a second-generation BMI1 inhibitor, PTC596, in treating patients with newly diagnosed DMG. This evidence concerns the gene BMI1 and neoplasm.